Navigate peer-reviewed breakthroughs by pharmacological class, genetic target, circulating biomarker, or diagnostic modality. Select any clinical entity to inspect all linked studies.
Everyday Health & Science Hubs
Indexed Entities (24)
Gene / Target13 Peer-Reviewed Briefings
KRAS, EGFR & BRCA Oncogenes
Somatic oncogenic driver mutations and homologous recombination deficiency targets.
Active Specialties:OncologyImmunologyPharmacologyInfectious DiseaseEndocrinology
Using a library of ready-made T-cell receptors targeting recurring mutations in TP53, clinicians have developed a personalized autologous T-cell therapy that skips the usual months of bespoke receptor hunting and has produced responses lasting 6 to 19 months in early clinical testing. Published in Cancer discovery, these peer-reviewed oncology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Collectively, these findings provide a rationale for combination strategies targeting mitochondrial dynamics to augment antitumor immunity. The balance between mtDNA and cytochrome c (cyt.c) release defined two immunologically distinct outcomes: immunogenic cell death (ICD) and apoptosis.
2/5 Preclinical
Evidence Meter · 2/5
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.
We highlight the need for more potent and selective KDM inhibitors, biomarkers of therapeutic response, novel combinatorial treatments and innovative drug discovery strategies. As we enter the third decade of investigations into histone demethylation, unlocking the full therapeutic potential of inhibiting KDMs will require a deeper understanding of their biology, substrate specificity, interaction networks and regulatory crosstalk.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
It defines the conditions under which China-originated programs can generate globally practice-changing evidence. This review links regulatory reform, disease-specific opportunity, target biology, therapeutic format, and evidence quality across a decade of solid tumor development.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
In this Phase 2 nonrandomized clinical trial, HB0025 plus chemotherapy showed promising antitumor activity and manageable safety in patients with advanced, driver variant-negative NSCLC in both nonsquamous and squamous histologic types, supporting further evaluation in randomized Phase 3 clinical trials. This open-label, multicenter, Phase 2 nonrandomized clinical trial enrolled patients with stage IIIB/C or IV NSCLC without sensitizing EGFR, ALK, or ROS1 alterations across 13 hospitals in China.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
The management of ERBB2-positive metastatic breast cancer is transitioning toward a more individualized approach that balances efficacy (real-world effectiveness in the trial), toxic effects, and patient preferences. Integrating biomarker (measurable biological signal)-driven strategies will be essential to optimize treatment selection, duration, and sequencing, with the goal of improving long-term outcomes while preserving quality of life.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
As well, two bispecific ADCs, respectively targeting EGFR-c-MET and EGFR-B7-H3, appear active against multiple solid tumor types. The antibody-drug conjugate field is increasingly looking to go after more than one target at a time.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
Exploratory analysis demonstrated that ex vivo mKRAS-specific T cell responses were robust (98.9%, 89/90) and associated with antigen spreading (86.7%, 13/15). In camupepimut-treated patients, mKRAS-specific T cell response >9.17-fold over baseline (82.2%, 74/90) correlated with improved DFS (HR 0.22, P < 0.0001), with the median DFS not reached versus 6.08 months for above and below 9.17-fold, respectively.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
This randomized clinical trial found that treatment with RT-DXd demonstrated promising activity, with mostly low-grade toxic effects in immune-positive, ERBB2-negative EBC. Unlike immune-negative patients, many immune-positive patients who experienced pCR avoided standard chemotherapy, including anthracyclines, supporting further evaluation in biomarker (measurable biological signal)-selected populations.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
These findings define a multiomic classification of NDMM linked to Isa-KRd response. . Genomic instability features and driver genes such as CCND1 and MYC correlated with differential MRD outcomes.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
These findings indicate that EGFR-targeted D2C7-ATC therapy prolongs survival in a subset of patients with IDHwt rGBM via intratumoral and systemic immune activation. . Eight patients died on trial; all deaths were unrelated to D2C7-ATC.
4/5 Strong Trial
Evidence Meter · 4/5
Strong Clinical Evidence
Tested directly in patients through a prospective clinical trial or large multicenter human cohort.
Our work underscores the importance of targeting postlactational involution as a strategy for the prevention of postpartum breast cancer and positions cabergoline as a novel, low-risk chemoprevention strategy. Notably, independent retrospective studies in two large cohorts of European women showed that cabergoline treatment was associated with a lower incidence of postpartum breast cancer, with a meta-analysis indicating an approximate 69% reduction in risk.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
Routine clinicogenomic data are, therefore, a scalable resource for discovery in cancer cachexia. Motivated by these observations, we developed a multivariate model to predict impending risk of cachectic weight loss in patients with lung, colorectal and prostate cancer, validated in an independent, external cohort from Dana-Farber Cancer Institute (n = 5,785).
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
1 min read·Nature Medicine·
Patient & Student Companion
Everyday Lab & Drug Translator
Instant plain-English guides for common blood tests and prescriptions—what normal ranges mean, what high/low values signal, and what to ask your clinician.
Lab Marker3-Month Blood Sugar
HbA1c
Measures the percentage of red blood cell hemoglobin coated with glucose over roughly 90 days.
Normal: below 5.7% · Prediabetes: 5.7%–6.4%
6.5% or higher on two tests diagnoses diabetes; very low values can occur alongside hypoglycemia or hemolytic anemia.
Ask your doctor: “Does my HbA1c match my daily fasting/post-meal glucose trends?”
Estimated glomerular filtration rate—how many milliliters of blood your kidneys filter every minute.
Healthy adult filter rate: 90+ mL/min/1.73m²
Values persistently below 60 for 3+ months (or elevated urine albumin) mark chronic kidney disease; single dips can simply reflect dehydration or NSAID use.
Ask your doctor: “Should we pair eGFR with a urine albumin-to-creatinine test (uACR)?”